Suppr超能文献

致病性放线菌对抗菌化合物的敏感性。

Susceptibility of pathogenic actinomycetes to antimicrobial compounds.

作者信息

Lerner P I

出版信息

Antimicrob Agents Chemother. 1974 Mar;5(3):302-9. doi: 10.1128/AAC.5.3.302.

Abstract

Current interest in antimicrobial susceptibility testing of anaerobic pathogens and recent recognition that actinomycetes other than Actinomyces israelii may cause actinomycosis in man prompted this in vitro survey of 74 strains of actinomycetes, representing seven species. Minimum inhibitory concentrations (MICs) for 24 antimicrobials were determined by inhibition of gross colonial enlargement in semisolid antibiotic agar after incubation at 37 C for 48 h under anaerobic conditions. Erythromycin and rifampin were the most active drugs in vitro (MICs of 0.008 to 0.25 mug/ml), although a small number of non-israelii strains were conspicuously more resistant to the latter (MICs >0.5 mug/ml). Penicillin G, cephaloridine, minocycline, and clindamycin were also very active in vitro (MICs of 0.03 to 1.0 mug/ml); for a few non-israelii strains the MICs of clindamycin were 2.0 to 8.0 mug/ml. MICs of cephalothin, ampicillin, lincomycin, tetracycline, doxycycline, and chloramphenicol were well within a therapeutic range for all strains of A. israelii and most other species, although the MIC of lincomycin against a few non-israelii strains and of tetracycline and doxycycline against the majority of these strains was 2.0 to 8.0 mug/ml. Oxacillin, dicloxacillin, and cephalexin were less active in vitro, particularly against strains other than A. israelii. Most non-israelii species were not suppressed by 125 mug of metronidazole per ml, which concentration inhibited all strains of A. israelii; otherwise, there were no antimicrobial susceptibility differences among the species tested. Aminoglycoside activity was negligible.

摘要

目前对厌氧性病原体进行抗菌药敏试验的关注,以及最近认识到除以色列放线菌外的其他放线菌可能在人类中引起放线菌病,促使对代表7个物种的74株放线菌进行了这项体外研究。通过在厌氧条件下于37℃孵育48小时后,抑制半固体抗生素琼脂中菌落的总体扩大,来测定24种抗菌药物的最低抑菌浓度(MIC)。红霉素和利福平是体外活性最强的药物(MIC为0.008至0.25μg/ml),尽管少数非以色列菌株对后者的耐药性明显更强(MIC>0.5μg/ml)。青霉素G、头孢噻啶、米诺环素和克林霉素在体外也非常活跃(MIC为0.03至1.0μg/ml);对于少数非以色列菌株,克林霉素的MIC为2.0至8.0μg/ml。头孢噻吩、氨苄西林、林可霉素、四环素、多西环素和氯霉素的MIC对所有以色列放线菌菌株和大多数其他物种来说都在治疗范围内,尽管林可霉素对少数非以色列菌株以及四环素和多西环素对这些菌株中的大多数的MIC为2.0至8.0μg/ml。苯唑西林、双氯西林和头孢氨苄在体外活性较低,特别是对非以色列放线菌菌株。大多数非以色列物种不受每毫升125μg甲硝唑的抑制,该浓度可抑制所有以色列放线菌菌株;否则,受试物种之间在抗菌药敏方面没有差异。氨基糖苷类药物的活性可忽略不计。

相似文献

1
Susceptibility of pathogenic actinomycetes to antimicrobial compounds.
Antimicrob Agents Chemother. 1974 Mar;5(3):302-9. doi: 10.1128/AAC.5.3.302.
2
Antimicrobial in vitro susceptibility of actinomyces israelii and arachnia propionica.
Scand J Infect Dis. 1977;9(1):40-5. doi: 10.3109/inf.1977.9.issue-1.10.
4
Susceptibility of anaerobic bacteria to 23 antimicrobial agents.
Antimicrob Agents Chemother. 1976 Oct;10(4):736-52. doi: 10.1128/AAC.10.4.736.
5
In vitro activity of amoxicillin, clindamycin, doxycycline, metronidazole, and moxifloxacin against oral Actinomyces.
J Endod. 2007 May;33(5):557-60. doi: 10.1016/j.joen.2007.02.002. Epub 2007 Mar 26.
6
Microdilution technique for antimicrobial susceptibility testing of anaerobic bacteria.
Antimicrob Agents Chemother. 1975 Mar;7(3):311-15. doi: 10.1128/AAC.7.3.311.
7
Antimicrobial susceptibility testing of Actinomyces species with 12 antimicrobial agents.
J Antimicrob Chemother. 2005 Aug;56(2):407-9. doi: 10.1093/jac/dki206. Epub 2005 Jun 21.
8
In vitro antimicrobial susceptibility of anaerobic bacteria isolated from clinical specimens.
Antimicrob Agents Chemother. 1972 Feb;1(2):148-58. doi: 10.1128/AAC.1.2.148.
9
Antibiotic susceptibility of Clostridium species isolated from human infections.
Scand J Infect Dis. 1975;7(2):127-34. doi: 10.3109/inf.1975.7.issue-2.09.
10
Susceptibility of Actinomyces israelii to antibiotics, sodium hypochlorite and calcium hydroxide.
Int Endod J. 1996 Sep;29(5):320-6. doi: 10.1111/j.1365-2591.1996.tb01392.x.

引用本文的文献

2
Cervicofacial Actinomycosis in the Pediatric Population: Presentation and Management.
Ann Otol Rhinol Laryngol. 2022 Mar;131(3):312-321. doi: 10.1177/00034894211021273. Epub 2021 Jun 1.
5
Cervical spondylitis and spinal abscess due to Actinomyces meyeri.
Braz J Infect Dis. 2014 Jan-Feb;18(1):106-9. doi: 10.1016/j.bjid.2013.05.016. Epub 2013 Nov 7.
6
Thoracic vertebral actinomycosis: Actinomyces israelii and Fusobacterium nucleatum.
J Clin Microbiol. 2008 Jun;46(6):2009-14. doi: 10.1128/JCM.01706-07. Epub 2008 Mar 12.
7
Lacrimal canaliculitis due to Arachnia (Actinomyces) propionica.
Br J Ophthalmol. 1981 Jan;65(1):10-3. doi: 10.1136/bjo.65.1.10.
9
Minimal inhibitory concentrations of various antimicrobial agents for human oral anaerobic bacteria.
Antimicrob Agents Chemother. 1983 Sep;24(3):420-4. doi: 10.1128/AAC.24.3.420.
10
Actinomyces naeslundii as an agent of pelvic actinomycosis in the presence of an intrauterine device.
J Clin Microbiol. 1985 Feb;21(2):273-5. doi: 10.1128/jcm.21.2.273-275.1985.

本文引用的文献

1
A case of actinomycosis treated with streptomycin.
Can Med Assoc J. 1947 Apr;56(4):431.
2
SENSITIVITY CHANGES OF ACTINOMYCES BOVIS TO PENICILLIN AND STREPTOMYCIN.
J Bacteriol. 1949 May;57(5):501-8. doi: 10.1128/jb.57.5.501-508.1949.
3
The sensitivity of actinomyces israeli to antibiotics.
Br Med J. 1952 Jun 14;1(4771):1263-4. doi: 10.1136/bmj.1.4771.1263.
5
The chemotherapy of actinomycosis and nocardiosis.
Am Rev Tuberc. 1951 Apr;63(4):441-8. doi: 10.1164/art.1951.63.4.441.
6
In vitro susceptibility of human pathogenic actinomycetes to chloramphenicol (chloromycetin).
Am J Clin Pathol. 1950 Nov;20(11):1076-8. doi: 10.1093/ajcp/20.11_ts.1076.
7
Actinomycosis and nocardiosis. A review of basic differences in therapy.
Am J Med. 1960 Jan;28:99-115. doi: 10.1016/0002-9343(60)90226-6.
8
A NEW PATHOGENIC ANAEROBIC ACTINOYCES SPECIES.
J Infect Dis. 1965 Feb;115:88-99. doi: 10.1093/infdis/115.1.88.
9
IDENTIFICATION OF SPECIES OF ACTINOMYCES.
J Bacteriol. 1964 Aug;88(2):477-90. doi: 10.1128/jb.88.2.477-490.1964.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验